Cellaria unites scientific thought leaders and innovators from diverse backgrounds who share a passion for empowering the cancer research community—and accelerating the search for a cure. Through strategic collaborations, we work towards changing the landscape of cancer treatment with more personalized therapeutics. As cancer research is ever-changing and ever-evolving, we know we must remain nimble, relentless, and aligned with both the challenges of researchers and the needs of patients.
Meet Our Team
David Deems, CEO
Mr. Deems is a senior executive with a proven ability to commercialize and successfully launch novel technology products for the life sciences and diagnostic markets. During his career, he has developed and launched over 100 new products, in regulated and research markets, and for large public and small venture-backed companies. Most recently, Mr. Deems was the President and CEO of Xceed Molecular (now part of Axela), a Canadian company with a novel gene expression platform used by clinical laboratories for testing novel biomarkers.
He joined Xceed from Predicant Biosciences, an early-stage proteomics company working to identify protein patterns in blood for the early detection of cancer, where he was responsible for managing Predicant’s product and commercial development efforts. Prior to Predicant, David held senior management positions with several companies focused on bringing novel products successfully into the marketplace. He served as Vice President of Product Development at EXACT Sciences; CEO of Union Biometrica prior to that company’s acquisition by Harvard Biosciences; and Vice President at BD Biosciences, a division of Becton, Dickinson and Company. He holds a Bachelor’s Degree from Boston University.
Jake Loewenheim, Director of Business Development
Dmitry Shvartsman, Director of Research & Development
Abigail E. Witt Ph.D., Director of Research & Development
Abigail is a Ph.D. scientist with 20+ years of research experience involving cell culture techniques, cancer biology, oncogenes, epigenetic mechanisms, cancer stem cells, epithelial cell adhesion, and cell signaling pathways. She received her doctorate from Johns Hopkins University for research examining the role of Methyl-CpG-Binding proteins and methylation in breast cancer invasion and progression. Her post-doctoral work focused on the role of specific Histone Deacetylases in the functional phenotype of cancer stem cells (CSCs) in breast and ovarian cancer. She has extensive experience in general biochemical analysis techniques, novel cell line derivation, culture media creation and optimization, 3D cell culture techniques (morphogenesis, sphere/soft agar assays), functional assays (invasion/migration, proliferation, cell adhesion/anchorage dependence, apoptosis), gene modulation, and drug screen development.
Connect With Us
Learn more about how Cellaria can help transform your research efficacy.